Verastem, Inc. Stock price

Equities

VSTM

US92337C2035

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
10.62 USD -3.45% Intraday chart for Verastem, Inc. -7.17% +30.47%
Sales 2024 * - Sales 2025 * 30.04M Capitalization 269M
Net income 2024 * -127M Net income 2025 * -107M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 8.94 x
P/E ratio 2024 *
-2.51 x
P/E ratio 2025 *
-4.33 x
Employees 57
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.26%
More Fundamentals * Assessed data
Dynamic Chart
Verastem, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Verastem, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Verastem Oncology's Ovarian Cancer Drug Gets FDA Orphan Drug Designation DJ
Verastem Gets Orphan Drug Designation From US FDA for Avutometinib to Treat Type of Ovarian Cancer MT
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers CI
Sector Update: Health Care Stocks Mixed Premarket Friday MT
Sector Update: Health Care MT
Verastem Gets Fast Track Label For Avutometinib Combination in Non-Small Cell Lung Cancer MT
Verastem Gets FDA Fast-Track Approval on Lung Cancer Treatment DJ
Verastem Oncology Selects Oral Kras G12d Inhibitor Gfh375/Vs-7375 as Lead Program in Discovery and Development Collaboration with Genfleet Therapeutics CI
Verastem Starts Confirmatory Trial of Ovarian Cancer Treatment Candidate MT
Verastem Oncology Announces Initiation of A Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer CI
Truist Securities Cuts Price Target on Verastem to $34 From $39, Maintains Buy Rating MT
Verastem Oncology Announces the Launch of the New Healthcare Professional Component CI
Verastem, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
More news
1 day-3.45%
1 week-7.17%
Current month-14.77%
1 month-14.70%
3 months+35.98%
6 months+7.27%
Current year+30.47%
More quotes
1 week
9.81
Extreme 9.81
11.13
1 month
9.81
Extreme 9.81
13.82
Current year
7.88
Extreme 7.88
14.22
1 year
4.20
Extreme 4.2
15.18
3 years
3.47
Extreme 3.474
59.22
5 years
3.47
Extreme 3.474
59.22
10 years
3.47
Extreme 3.474
152.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 10-12-31
Director of Finance/CFO 37 18-11-30
Chief Tech/Sci/R&D Officer - 21-09-21
Members of the board TitleAgeSince
Director/Board Member 67 17-05-02
Director/Board Member 66 20-04-22
Chairman 64 12-11-25
More insiders
Date Price Change Volume
24-03-18 10.62 -3.45% 105,153
24-03-15 11 +4.76% 189,806
24-03-14 10.5 -2.23% 152,309
24-03-13 10.74 -0.92% 98,890
24-03-12 10.84 -5.24% 139,714

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company's advanced product candidates, Avutometinib (VS-6766) and Defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, but not limited to low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, and melanoma. VS-6766 is an orally available small molecule RAF/MEK clamp. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2) that is being evaluated as a potential combination therapy for various solid tumors.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
10.62 USD
Average target price
28.79 USD
Spread / Average Target
+171.05%
Consensus
  1. Stock
  2. Equities
  3. Stock Verastem, Inc. - Nasdaq